Related Experiment Video
Updated: Dec 31, 2025

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings
Published on: August 19, 2021
The Novel Enterococcus Phage vB_EfaS_HEf13 Has Broad Lytic Activity Against Clinical Isolates of Enterococcus
Dongwook Lee1, Jintaek Im1, Hongjun Na2
1Department of Oral Microbiology and Immunology, DRI, and BK21 Plus Program, School of Dentistry, Seoul National University, Seoul, South Korea.
Abstract:
Enterococcus faecalis is a Gram-positive, facultative anaerobic bacterium frequently found in the gastrointestinal tract, oral cavity, and periodontal tissue. Although it is considered a commensal, it can cause bacteremia, endocarditis, endodontic infections, and urinary tract infections. Because antibiotics are cytotoxic not only to pathogens, but also to health-beneficial commensals, phage therapy has emerged as an alternative strategy to specifically control pathogenic bacteria with minimal damage to the normal flora. In this study, we isolated a novel phage, Enterococcus phage vB_EfaS_HEf13 (phage HEf13), with broad lytic activity against 12 strains of E. faecalis among the three laboratory strains and 14 clinical isolates of E. faecalis evaluated. Transmission electron microscopy showed that phage HEf13 has morphological characteristics of the family Siphoviridae. Phage HEf13 was stable at a wide range of temperature (4-60°C) and showed tolerance to acid or alkaline (pH 3-12) growth conditions. Phage HEf13 had a short latent period (25 min) with a large burst size (approximately 352 virions per infected cell). The lytic activity of phage HEf13 at various multiplicities of infection consistently inhibited the growth of diverse clinical isolates of E. faecalis without any lysogenic process. Moreover, phage HEf13 showed an effective lytic activity against E. faecalis on human dentin ex vivo infection model. Whole genome analysis demonstrated that the phage HEf13 genome contains 57,811 bp of double-stranded DNA with a GC content of 40.1% and 95 predicted open reading frames (ORFs). Annotated functional ORFs were mainly classified into four groups: DNA replication/packaging/regulation, phage structure, host cell lysis, and additional functions such as RNA transcription. Comparative genomic analysis demonstrated that phage HEf13 is a novel phage that belongs to the Sap6virus lineage. Furthermore, the results of multiple sequence alignment showed that polymorphism of phage infection protein of E. faecalis (PIPEF) contributes to determine the host specificity of phage HEf13 against various E. faecalis strains. Collectively, these results suggest that phage HEf13 has characteristics of a lytic phage, and is a potential therapeutic agent for treatment or prevention of E. faecalis-associated infectious diseases.
Insights
A novel lytic bacteriophage, Enterococcus phage HEf13, effectively targets and eliminates Enterococcus faecalis, a common pathogen. This phage shows broad lytic activity and stability, presenting a promising alternative to antibiotics for treating E. faecalis infections.
Area of Science:
- Microbiology
- Virology
- Bacteriology
Background:
- Enterococcus faecalis is a Gram-positive bacterium causing various infections.
- Antibiotic resistance necessitates alternative treatments like phage therapy.
- Phage therapy offers targeted bacterial control with minimal disruption to normal flora.
Purpose of the Study:
- To isolate and characterize a novel bacteriophage with lytic activity against Enterococcus faecalis.
- To evaluate the therapeutic potential of the isolated phage against E. faecalis infections.
Main Methods:
- Isolation and characterization of Enterococcus phage vB_EfaS_HEf13 (phage HEf13).
- Transmission electron microscopy for morphology assessment.
- Stability testing across temperature and pH ranges.
- Genome sequencing and analysis.
- In vitro and ex vivo infection models to assess lytic activity.
Main Results:
- Phage HEf13 exhibits broad lytic activity against E. faecalis strains.
- It is morphologically identified as a Siphoviridae family member.
- Phage HEf13 demonstrates stability over a wide temperature (4-60°C) and pH (3-12) range.
- It possesses a short latent period (25 min) and a large burst size (~352 virions/cell).
- Genome analysis reveals a novel phage belonging to the Sap6virus lineage.
- Polymorphism in phage infection protein (PIP_EF) influences host specificity.
Conclusions:
- Phage HEf13 is a stable, lytic bacteriophage with significant potential for treating E. faecalis infections.
- Its specific lytic activity and favorable characteristics make it a promising candidate for phage therapy.
- Further research into phage HEf13 could lead to novel strategies against E. faecalis-associated diseases.
Related Concept Videos
Viral Replication: Lytic Cycle
Lytic Cycle of Bacteriophages
DNA Bacteriophages
Lysogenic Cycle of Bacteriophages

